1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer

After MURANO: Roche/AbbVie Map Venclexta's Expansion Past CLL

 
• By Emily Hayes

Sponsors expect that if Venclexta demonstrates compelling early data in new indications – like acute myeloid leukemia and multiple myeloma – the US FDA will be willing to help speed access for patients.

BCL-2 protein_164970335_1200.jpg
The BCL-2 protein, illustrated above, prevents cell death and is often over-expressed in cancer cells.

Withthe MURANO study of the first-in-class BCL-2 inhibitor Venclexta in the broad relapsed chronic lymphocytic leukemia population done and dusted and front-line studies chugging along, partners Roche and AbbVie Inc. are busy writing the drug's next chapters, with a special focus on expansion into acute myeloid leukemia and multiple myeloma.

Venclexta (venetoclax) is an oral drug that blocks the BCL-2 protein in order to restore the signaling system

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

China Biopharma Podcast - 14 May 2025 (Chinese Language)

 
• By Dexter Jie Yan and Xu Hu

Join our China-based editors Dexter Yan and Xu Hu in this Chinese-language podcast looking at some of their recent interviews and other key coverage.

iTeos/GSK To Terminate Collaboration After TIGIT Trials Flop

 
• By Alaric DeArment

Belrestotug is the latest anti-TIGIT candidate to fail to meet expectations. iTeos said it will pursue strategic alternatives.

‘Market Developments’ Persuade Galapagos To Rethink Spin-Off

 
• By Andrew McConaghie

CEO Paul Stoffels exits early to be succeeded by Henry Gosebruch, who will now consider ‘all options’ for the Belgian firm as it tries to claw back investor confidence.

Strong Showing For Bayer’s Pharma Business In Uncertain Times

 
• By Kevin Grogan

As CEO Anderson backs high prices for innovative drugs in Europe

More from Therapy Areas

Stock Watch: Stock Watch: Lilly And Novo Duke Out Q1

 
• By Andy Smith

Novo Nordisk enjoyed a surprise GLP-1 agonist contracting win in the first quarter of 2025. This provided a welcome boost to its stock after it had spent the previous quarter on the back foot against rival Lilly.

Sustainability Key To ABL Bio’s Journey From ‘Good To Great’

 
• By Jung Won Shin

Helped by a recent major platform deal with GSK, South Korea's ABL Bio is aiming to build its R&D portfolio with an eye on being acquired in the future. CEO Sang Hoon Lee sat down with Scrip to explain the venture's journey so far and its ambitious roadmap.

Lilly Builds Obesity Momentum With New SURMOUNT Data Besting Novo Nordisk

 
• By Alaric DeArment

The presentation and publication of the Phase IIIb study showing greater efficacy for Zepbound over Wegovy come at a time when competition has been heating up between the two obesity medications.